Okuma Y - Search Results

1

Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy.

Okuma Y, Ko R, Shukuya T, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Kojima T, Fujita Y, Hino T, Yamanda S, Suzuki T, Fukuizumi A, Sakakibara T, Harada T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Okuma Y, et al. Lung Cancer. 2020 Oct;148:122-128. doi: 10.1016/j.lungcan.2020.08.014. Epub 2020 Aug 20. Lung Cancer. 2020. PMID: 32890794

2

S-1 is an active anticancer agent for advanced thymic carcinoma.

Okuma Y, Shimokawa T, Takagi Y, Hosomi Y, Iguchi M, Okamura T, Shibuya M. Okuma Y, et al. Lung Cancer. 2010 Dec;70(3):357-63. doi: 10.1016/j.lungcan.2010.09.004. Epub 2010 Oct 15. Lung Cancer. 2010. PMID: 20951466

3

Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.

Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M. Okuma Y, et al. Lung Cancer. 2011 Dec;74(3):492-6. doi: 10.1016/j.lungcan.2011.05.013. Epub 2011 Jun 12. Lung Cancer. 2011. PMID: 21665316

4

[Chemotherapy for thymic carcinoma].

Okuma Y. Okuma Y. Gan To Kagaku Ryoho. 2012 May;39(5):702-7. Gan To Kagaku Ryoho. 2012. PMID: 22584319 Japanese.

5

A case of successful preoperative chemotherapy with cisplatin and irinotecan followed by curative-intent surgery for locally advanced thymic carcinoma.

Suzuki S, Horio H, Hato T, Harada M, Okuma Y, Hishima T. Suzuki S, et al. Among authors: okuma y. Gen Thorac Cardiovasc Surg. 2013 Mar;61(3):166-9. doi: 10.1007/s11748-012-0123-2. Epub 2012 Jul 4. Gen Thorac Cardiovasc Surg. 2013. PMID: 22760255

6

Clinical outcomes with chemotherapy for advanced thymic carcinoma.

Okuma Y, Hosomi Y, Takagi Y, Sasaki E, Hishima T, Maeda Y, Shibuya M, Okamura T. Okuma Y, et al. Lung Cancer. 2013 Apr;80(1):75-80. doi: 10.1016/j.lungcan.2012.12.012. Epub 2013 Jan 11. Lung Cancer. 2013. PMID: 23313005 Free article.

7

Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.

Takagi Y, Toriihara A, Nakahara Y, Yomota M, Okuma Y, Hosomi Y, Shibuya M, Okamura T. Takagi Y, et al. Among authors: okuma y. PLoS One. 2013;8(3):e59700. doi: 10.1371/journal.pone.0059700. Epub 2013 Mar 26. PLoS One. 2013. PMID: 23555751 Free PMC article.

8

The potency of curative-intent treatment for advanced thymic carcinoma.

Okuma Y, Horio H, Hosomi Y, Watanabe K, Maeda Y, Okamura T, Hishima T. Okuma Y, et al. Lung Cancer. 2014 May;84(2):175-81. doi: 10.1016/j.lungcan.2014.02.012. Epub 2014 Mar 2. Lung Cancer. 2014. PMID: 24646831

9

Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center.

Okuma Y, Hosomi Y, Watanabe K, Yamada Y, Horio H, Maeda Y, Okamura T, Hishima T. Okuma Y, et al. BMC Cancer. 2014 May 20;14:349. doi: 10.1186/1471-2407-14-349. BMC Cancer. 2014. PMID: 24885581 Free PMC article.

10

Crucial role of treatment with palliative intent for a patient with advanced thymic carcinoma.

Nagamata M, Okuma Y, Yamada Y, Hosomi Y, Hishima T. Nagamata M, et al. Among authors: okuma y. Oncol Lett. 2014 Aug;8(2):513-516. doi: 10.3892/ol.2014.2217. Epub 2014 Jun 3. Oncol Lett. 2014. PMID: 25013463 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

557 results

Search Page